PSMB9 and neoplasm: Viral vector-based vaccines, including modified vaccinia Ankara (MVA-EL) encoding EBNA1 and LMP2, as well as recombinant adenoviral vectors targeting LMP2, have demonstrated target antigen-specific T cell responses, but clinical anti-tumor efficacy data are limited [60,61].